RE:RE:RE:RE:RE:RE:GSK pays $2 Billion for single indication cough company Earlier this month " GSK “permanently” discontinued enrollment in ZEST, a late-stage study from 2021 aiming to recruit 800 patients with either HER2-negative, BRCA-mutated breast cancer or triple-negative breast cancer with molecular disease (involving GSK's PARP inhibitor niraparib). The move doesn’t portend any problems with Zejula itself, instead reflecting “eligibility challenges” that made enrollment 'much more challenging than previously thought,' said GSK."
"GSK’s study leveraged new circulating tumor DNA (ctDNA) testing technology to pinpoint patients at higher risk of disease recurrence for potential treatment with Zejula while their disease burden was still low. CtDNA refers to DNA fragments releasd into the bloodstream by dying tumors."
"GSK stressed the issue was related to enrollment hurdles, not Zejula itself, and clarified that the ZEST cancellation “does not impact any other ongoing trials with niraparib,” referring to the medicine’s generic name."
https://www.fiercepharma.com/pharma/gsk-lurking-metastatic-disease-breast-cancer-patients-spells-trouble-zejula-trial
This development further opens up the breast cancer space for ONCY's pelareorep in the treatment of HER2-negative or triple-negative breast cancer, now that Big Pharma is moving towards the treatment of early stage breast cancer rather than late-stage cancers.